Pediatrix Taps AI and Equity Experts to Reshape Pediatric Care

FORT LAUDERDALE, FL – March 24, 2026 – Pediatrix Medical Group, Inc. (NYSE: MD) has announced a significant strategic move to fortify its clinical leadership, appointing two of the nation's most respected physician leaders to its executive team. James Barry, M.D., MBA, a pioneer in applying artificial intelligence to neonatal care, will join as Chief Clinical Quality & Transformation Officer. He is joined by Jochen Profit, M.D., MPH, a leading researcher in health equity and care delivery, who will serve as Chief Quality Advisor. The appointments signal a deliberate and powerful pivot for the major physician services provider, aiming to harness advanced technology and systemic quality improvements to redefine the standard of care for women, babies, and children across its national network.

“Quality care is at the heart of everything that we do as a leading provider of care for women, babies and children,” stated Mark Ordan, Chair of the Board and CEO, in the company's announcement. “Drs. Barry and Profit’s enormous experience and expertise will help us continue to advance both clinical knowledge and practice for the entire field.”

A New Era of Leadership and Vision

Dr. James Barry brings a unique and potent combination of clinical expertise and technological foresight to Pediatrix. A neonatologist with 25 years of experience and a professor of pediatrics-neonatology at the University of Colorado Anschutz School of Medicine, his career has been dedicated to improving outcomes for high-risk infants. His recent MBA from the University of Colorado Denver further sharpens his ability to implement strategic change within complex health systems.

Dr. Barry's influence extends far beyond the NICU. He is a co-founder of NeoMINDAI, a groundbreaking national learning collaborative that unites neonatologists and data scientists to evaluate the application of artificial intelligence in pediatric medicine. This work positions him at the vanguard of a movement to integrate machine learning and predictive analytics into clinical practice. He also co-founded the Clinical Leader’s Group within the American Academy of Pediatrics, a vital resource for training medical directors of NICUs nationwide. In his new capacity, Dr. Barry will oversee the Pediatrix Center for Research, Education, Quality and Safety (CREQS), tasked with transforming the organization's medical direction and ensuring the highest standards of patient care.

“At a time when medical knowledge continues to grow exponentially and technology is reshaping care, Dr. Barry’s proven track record as a strategist and innovator will be an incredible asset to our organization and our patients as we move forward,” Ordan noted.

Championing Quality, Equity, and Systemic Change

Working alongside Dr. Barry is Dr. Jochen Profit, whose career represents a deep commitment to not only clinical excellence but also to the equitable delivery of care. As the Wendy J. Tomlin-Hess Endowed Professor of Pediatrics at Stanford Medicine, Dr. Profit has built a formidable reputation over two decades in pediatrics and neonatal-perinatal medicine. With a medical degree from Germany's Albert-Ludwigs-University and a Master of Public Health from Harvard University, his perspective is both global and intensely focused on systemic improvement.

Dr. Profit is a key architect of quality improvement infrastructure in California, serving as Chair of the California Perinatal Quality Care Collaborative (CPQCC) and Co-Chair of the California Maternal Quality Care Collaborative (CMQCC). His research focuses on optimizing care delivery for pregnant people and sick newborns, with a particular emphasis on health system design, care culture, and addressing the socioeconomic and racial disparities that lead to unequal outcomes. His role as Chief Quality Advisor will involve providing expert medical guidance to Pediatrix’s vast network of affiliated clinical leaders and contributing his expertise to the CREQS initiatives.

“Dr. Profit is widely recognized as among the foremost thought leaders in our field, and we are excited that he is bringing his talents to Pediatrix, where his unyielding focus on improving quality and patient safety will have a national impact,” said Ordan.

A Strategic Push Towards an AI-Powered Future

The recruitment of Dr. Barry, in particular, is a clear indicator that Pediatrix is betting on an AI-powered future. For a company with approximately 4,300 affiliated clinicians, the potential to leverage vast datasets to identify trends, predict complications, and standardize best practices is immense. Dr. Barry's expertise is not merely theoretical; his work with NeoMINDAI and his experience leading newborn governance across a 14-hospital system demonstrate a practical understanding of how to translate data into durable, measurable improvements in patient care.

This move aligns with a broader trend in healthcare, where large provider groups are increasingly looking to artificial intelligence to solve complex problems in patient safety and clinical efficiency. In the highly specialized and data-rich environment of neonatal and maternal-fetal medicine, AI can help clinicians detect subtle patterns that may precede a crisis, optimize ventilator settings for premature infants, or personalize care pathways for high-risk pregnancies. By placing a recognized AI expert in a key leadership role, Pediatrix is positioning itself to lead this technological transformation rather than follow it.

Dr. Barry's own words reflect this ambitious vision. “While our organization is built on a foundation of incredible clinical excellence and unmatched scale, I believe our true strength lies in our collective intelligence,” he stated. “By combining our clinical heart and genuine curiosity with transformative strategy, we will ensure that evidence-based approaches are more accessible and effective across all our clinical sites.”

A National Blueprint for Maternal and Child Health

The dual appointments also signal an ambition that extends beyond the walls of Pediatrix's affiliated hospitals and practices. With Dr. Profit's profound experience in health equity and large-scale quality collaboratives, the organization is poised to influence national standards for maternal and child health. His work in California has provided a successful blueprint for reducing maternal mortality and improving neonatal outcomes through collaborative, data-driven initiatives. Applying these principles across Pediatrix's national footprint could have a profound impact on reducing persistent health disparities in the United States.

By integrating Dr. Barry’s technological innovation with Dr. Profit’s focus on equitable systems, Pediatrix is creating a powerful synergy. This strategy suggests a move from being a provider of services to becoming an engine of industry-wide improvement. The insights generated from their national network could inform public health policy, drive new research, and establish new benchmarks for family-centered, equitable care. These hires are not just about enhancing internal quality; they are about leveraging the company's significant scale to create a positive, far-reaching impact on public health. The combination of these two leaders suggests a future where data-driven precision medicine and a passionate commitment to health equity are not competing ideals but are instead two sides of the same coin, driving the future of care for the nation's most vulnerable patients.